The French Cohort of DNA Repair-Deficient Xeroderma Pigmentosum Patients: Risk of Hematological Malignancies
Cancers · 10.05.2023 · 15 (10) · 2706
DOI: 10.3390/cancers15102706 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 10.05.2023. Verfasst von Alain Sarasin. Beteiligte Einrichtung: Unité Mixte de Recherche UMR9019 Centre National de la Recherche Scientifique, 94805 Villejuif, France. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Xeroderma pigmentosum (XP) is a rare genetic disorder characterized by a high incidence of skin cancers. These patients are deficient in nucleotide excision repair caused by mutations in one of the 7 XP genes.
Methods
We diagnosed 181 XP patients using UV-induced DNA repair measurements and/or DNA sequencing from 1982 to 2022 in France.
Results
As all XP patients, the French ones are very sensitive to UV exposure but since they are usually very well protected, they develop relatively few skin cancers. A majority of French XP patients originate from North Africa and bear a founder mutation on the XPC gene. The striking discovery is that these patients are at a very high risk to develop aggressive and lethal internal tumors such as hematological malignancies (more than a 100-fold risk compared to the general population for myelodysplasia/leukemia) with a median age of death of 25 years, and brain, gynecological, and thyroid tumors with even lower median ages of death. The high mutation rates found in XP-C internal tumors allow us to think that these XP patients could be successfully treated by immunotherapies. A full analysis of the molecular origins of these DNA repair-deficient tumors is discussed. Several explanations for this high predisposition risk are proposed.
Conclusions
As the age of the XP population is increasing due to better photo-protection, the risk of lethal internal tumors is a new Damocles sword that hangs over XP-C patients. This review of the French cohort is of particular importance for alerting physicians and families to the prevention and early detection of aggressive internal tumors in XP patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Unité Mixte de Recherche UMR9019 Centre National de la Recherche Scientifique, 94805 Villejuif, France.
- Gustave Roussy Institute, 94805 Villejuif, France.
- Université Paris-Saclay, 91400 Saclay, France.
ORCID-Profile: Alain Sarasin
Zitieren
APA
Sarasin, A. (2023). The French Cohort of DNA Repair-Deficient Xeroderma Pigmentosum Patients: Risk of Hematological Malignancies. Cancers, 15(10), 2706. https://doi.org/10.3390/cancers15102706
Vancouver
Sarasin A. The French Cohort of DNA Repair-Deficient Xeroderma Pigmentosum Patients: Risk of Hematological Malignancies. Cancers. 2023;15(10):2706. doi:10.3390/cancers15102706
BibTeX
@article{Sarasin2023,
author = {Sarasin, Alain},
title = {The French Cohort of DNA Repair-Deficient Xeroderma Pigmentosum Patients: Risk of Hematological Malignancies},
journal = {Cancers},
year = {2023},
volume = {15},
number = {10},
pages = {2706},
doi = {10.3390/cancers15102706}
}
EUVIMED